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Background: Borderline resectable pancreatic cancers are technically amenable to surgical resection,
but are associated with increased risk of locoregional recurrence. Patients with these tumours may be
treated with neoadjuvant therapy in an attempt to improve margin-negative resection rates.
Methods: The University of Cincinnati Pancreatic Cancer Database was retrospectively reviewed. Bor-
derline resectable disease was defined by the following radiographic criteria: (i) short segment occlusion
of the superior mesenteric vein (SMV), portal vein (PV) or SMV/PV confluence; (ii) short segment hepatic
artery encasement, or (iii) superior mesenteric artery/coeliac artery abutment of <180 degrees. Patients
with resectable disease who had questionable metastatic disease or poor performance status were also
included.
Results: Twenty-nine patients met the criteria. Of these, 26 underwent a full course of neoadjuvant
therapy. Twelve (46%) underwent surgical resection and 14 had tumour progression or were deemed
unresectable at laparotomy. The most common neoadjuvant therapy regimen was gemcitabine-based
chemotherapy alone (58%). Of those undergoing surgery, 67% had margin-negative (R0) resections and
42% required venous resection. Median survival was 15.5 months for unresected patients and 23.3
months for resected patients.
Discussion: Borderline resectable pancreatic tumours can be treated neoadjuvantly, resulting in margin-
negative resection and survival rates similar to those in initially resectable disease.
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Introduction
Over the last decade, relative consensus has evolved around the
definition of resectability for adenocarcinoma of the pancreatic
head. These criteria are based on objective, cross-sectional
imaging and include: (i) absence of extrapancreatic disease; (ii) no
involvement of the superior mesenteric artery (SMA), hepatic
artery and coeliac axis, and (iii) patency of the superior mesen-
teric vein (SMV)/portal vein (PV) confluence. There is a subgroup
of tumours which have been increasingly recognized and recently
described as ‘borderline resectable’. The operational definition of
borderline resectable is that these tumours can be resected, albeit
with an increased risk of a pathologically involved margin and
therefore a higher than average risk of local recurrence.1,2 It is well
established that surgical resection offers the only opportunity for
cure and the median survival for unresected patients is usually
<12 months. Therefore, efforts to enhance our ability to achieve
margin-negative resections for borderline lesions are of consider-
able interest.1,2
The National Comprehensive Cancer Network (NCCN) defines
borderline resectable cancer of the pancreatic head as having one
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of several anatomic characteristics: severe unilateral SMV/PV
impingement; SMA abutment; gastroduodenal artery encasement
at the level of the hepatic artery; short segment SMV occlusion;
involvement of the inferior vena cava, and invasion of the colon or
mesocolon.3 The MD Anderson Cancer Center has attempted to
provide a more objective, computed tomography (CT)-based
determination of borderline resectability, including tumours with
several specific anatomic features: abutment of the SMA or coeliac
axis involving <180 degrees of vessel circumference; abutment or
encasement of a short segment of the hepatic artery, and short
segment occlusion of the SMV, PV or SMV/PV confluence with
suitable distal and proximal vein to allow for reconstruction.1
The MD Anderson group recently published a retrospective
analysis of patients with borderline resectable pancreatic cancer
who had been treated at their centre. Of the 160 patients included,
41% underwent resection following a neoadjuvant course of
chemotherapy, chemoradiation or both. The median survival of
patients undergoing resection was 40 months, compared with 13
months for patients who had progressive unresectable disease fol-
lowing neoadjuvant treatment. The authors concluded that the
use of neoadjuvant therapy in patients with borderline resectable
pancreatic cancer allowed for the selection of patients most likely
to benefit from resection and supported the completion of
margin-negative resections in the majority of these patients.4 The
objective of this study was to retrospectively evaluate the out-
comes for patients with borderline resectable pancreatic cancer
treated at our centre over the past 5 years.
Materials and methods
Inclusion criteria
The diagnosis of borderline resectable pancreatic cancer was
based upon the presence of at least one of four criteria identified
on either contrast-enhanced thin-slice abdominal CT or endo-
scopic ultrasound: (i) short segment occlusion of SMV/PV
confluence with suitable proximal and distal vein allowing for
reconstruction; (ii) tumour encasement of a short segment of the
hepatic artery; (iii) tumour abutment of the SMA, involving <180
degrees of vessel circumference, or (iv) substantial involvement of
the SMV or PV of >180 degrees of vessel circumference. The first
three of these criteria are based upon those described previously
by Katz et al. at the MD Anderson Cancer Center.4 The fourth is
modified from the NCCN definition of borderline resectable
disease, which includes tumours with ‘severe unilateral SMV/PV
impingement’.3 Additionally, like the MD Anderson group, we
included an additional group of patients who had resectable
cancer of the pancreatic head, but also had questionable meta-
static or nodal disease on imaging, or who were deemed to
be medically unfit for surgical resection at the time of initial
presentation.4
Treatment algorithm
All patients included in our study had been histologically diag-
nosed with adenocarcinoma of the pancreas prior to initiation of
therapy. Patients deemed to be borderline resectable anatomically,
or resectable with questionable metastatic disease or performance
status, underwent a course of neoadjuvant chemotherapy or
chemoradiation as recommended by our multidisciplinary pan-
creas team. Following therapy, patients were re-staged by repeat
history and physical examination, repeat carbohydrate antigen
(CA) 19-9 level determination in some patients, and radiographi-
cally by contrast-enhanced CT of the chest and thin-cut CT of the
abdomen and pelvis. Decisions concerning the resectability of
tumours following the completion of neoadjuvant therapy were
made on a case-by-case basis by the multidisciplinary pancreas
treatment team. In general, patients whose tumours displayed
radiographic evidence of downstaging underwent laparotomy and
attempted resection. Resection was not attempted in patients with
radiographically progressive locoregional or distant metastatic
disease following neoadjuvant treatment. In our experience, stable
tumour size following neoadjuvant therapy can indicate the
replacement of tumour volume by necrosis or desmoplastic reac-
tion, rather than failure of the tumour to respond to treatment. To
that end, in patients whose tumour size did not change, additional
factors, such as decreased CA 19-9 levels and decreased uptake on
positron emission tomography (PET) scan were considered to
indicate downstaging and resection was attempted, even when the
mass appeared to abut the SMA or involve the SMV/PV. In a few
instances, in which tumour size remained stable, and CA 19-9 and
PET uptake did not decrease substantially, patients underwent
endoscopic ultrasound and biopsy of the mass; the absence of
malignant cells or the presence of necrotic or desmoplastic changes
were considered to indicate downstaging and resection was
attempted. All patients deemed resectable with no apparent intra-
abdominal metastases at laparotomy underwent pancreati-
coduodenectomy, as previously described.5 Because up to 30% of
patients are noted to have metastatic disease at the time of explo-
ration, diagnostic laparoscopy has been performed routinely for
12–24 months at our centre; some patients in this analysis were
treated before this practice became routine at our institution. We
consider this procedure to be appropriate both prior to laparotomy
for resection and in patients who do not respond to neoadjuvant
therapy; its purpose is to assess intra-abdominal metastasis and
guide future treatment options. All specimens underwent stan-
dardized pathological evaluation, as described previously.4 Briefly,
the bile duct and pancreatic transectionmargins were evaluated by
frozen section intraoperatively to ensure adequate resection. The
SMAmargin was identified and inked by the surgeon and patholo-
gist immediately following specimen removal. All three margins
were reviewed by permanent-section microscopic examination
during final pathological evaluation. If a vein resection was per-
formed, the vein margin was inked and identified for the patholo-
gist and permanent section analysis was undertaken.
Data collection and statistical analysis
Approval was attained for this study from the Institutional Review
Board (IRB) of the University of Cincinnati. Patient databases
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from 2003 to 2008 were retrospectively reviewed to identify
patients diagnosed with borderline resectable adenocarcinoma of
the pancreatic head at the time of initial presentation at our
centre.
Data including patient demographics, details of neoadjuvant
treatment regimens and operative procedures, and follow-up
status were collected. Pancreatic fistula was identified using pre-
viously described clinical parameters.6 Adjusted CA 19-9 levels
were calculated by dividing CA 19-9 by total serum bilirubin when
the bilirubin was >2 mg/dl, as previously described.7
SigmaPlot Version 11.0 (Systat Software Inc., San Jose, CA,
USA) was used for statistical analysis. Student’s t-test (two-tailed)
analysis was used to determine significant differences between
groups for parametric variables (age, tumour size, CA 19-9, dura-
tion of therapy). Fisher’s exact test was utilized to determine sig-
nificant differences between groups for non-parametric variables
(gender, symptoms, anatomic characteristics, presence of meta-
static disease or poor performance status, courses of therapy).
Survival was analysed by the Kaplan–Meier log-rank method.
Results
Patient characteristics
Between 2003 and 2008, 29 patients were diagnosed with border-
line resectable pancreatic cancer and underwent a course of neo-
adjuvant treatment at our centre. During the same period,
approximately 340 patients were treated at our centre for pancre-
atic cancer, including about 150 patients who underwent opera-
tive resections. The operative interventions performed, and
subsequent delineation into our defined resected and unresected
groups, are demonstrated in Fig. 1. Of the 29 patients, 26 com-
pleted their neoadjuvant treatment courses and were included in
the remainder of our study analyses. Resection was attempted in
16 patients and completed successfully in 12; the procedures were
aborted in the remaining four patients after metastatic disease was
seen in the liver at the time of laparotomy (three patients) or on
peritoneal surfaces by diagnostic laparoscopy (one patient). These
four patients, along with those in whom resection was not
attempted, comprised the ‘unresected’ group in our analysis.
Among the 10 patients in whom resection was not attempted,
three had evidence of distant metastasis at the time of restaging
(one to liver, one to lung, one to both), and seven had stable
tumour size. Of these seven, three had increased CA 19-9, and the
other four had evidence of continued tumour viability by either
PET scan or biopsy. This is by contrast with the 12 patients who
were ultimately resected; half of the tumours in these patients had
decreased in size on restaging and the other half remained stable
in size, but appeared to be non-viable by PET or biopsy.
There were no statistically significant differences between the
resected and unresected groups in terms of age, gender, symp-
toms, tumour size or adjusted CA 19-9 levels at presentation
(Table 1). In addition, there were no differences in the anatomic
characteristics of the borderline resectable tumours that qualified
patients for study inclusion (58% vs. 43% for >180-degree SMV
involvement, 8% vs. 29% for SMA abutment, 8% vs. 7% for
SMV/PV occlusion, and 0% vs. 7% for hepatic artery encasement,
of patients in the resected vs. unresected groups, respectively).
Overall, 25% and 14% of patients in the resected and unresected
groups, respectively, were included for questionable metastatic or
nodal disease. Only one patient had been included initially for
poor performance status; she died during neoadjuvant therapy
and was therefore excluded from the final data analysis. Both the
other two excluded patients died prior to completion of neoadju-
vant therapy; one of these had SMA abutment and the other had
extended SMV involvement.
Neoadjuvant therapies
The neoadjuvant therapies did not differ significantly between
patients who were ultimately resected compared with those who
were not (Table 2). The majority of patients overall (58%)
received gemcitabine-based chemotherapy; these included 75% of
patients in the resected group (9/12) and 43% of patients in the
unresected group (6/14). The most common chemotherapy regi-
mens in both groups were gemcitabine alone (23%), gemcitabine
with Tarceva (15%), and gemcitabine with oxaliplatin and Tarceva
(12%).Our current algorithm for patients with good performance
status involves doublet or triplet therapy as this has been demon-
strated to be associated with increased tumour response.
Although the difference was not significant, more patients in
our unresected group tended to have received chemoradiation
therapy alone (29%, or 4/14 patients, vs. 8%, or 1/12 patients in
the resected group). Most patients receiving chemoradiation
alone were treated early in the data collection period; the algo-
rithm for neoadjuvant treatment changed to favour gemcitabine-
based chemotherapy over time as it seemed to be more successful
at downstaging borderline patients and controlling the progres-
sion of disease in unresectable patients at our centre. It is our
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Figure 1 Delineation of patients into treatment groups
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current belief that radiation therapy does not cause significant
tumour shrinkage and we have accordingly eliminated this from
upfront therapy. This has allowed us tomaximize systemic therapy
dosing without increasing toxicity. The chemotherapeutic agent
administered to the one resected patient during radiation was
5-fluorouracil; in the unresected group, two patients received
5-fluorouracil and two received gemcitabine. The duration of
neoadjuvant treatment did not differ significantly between the
two groups (104 37 days in the resected group vs. 121 73 days
in the unresected group).
Six of the 26 patients (23%) who ultimately completed their
neoadjuvant treatment were admitted to hospital during their
course of therapy, four for cholangitis (15%), one with a bleeding
duodenal ulcer and one with community-acquired pneumonia
and pulmonary emboli. Four patients (15%) presented to the
emergency department during neoadjuvant therapy and were
treated as outpatients; the most common presenting symptoms
were dehydration, fatigue and diarrhoea. Seventeen of the 26
patients (65%) who completed neoadjuvant therapy tolerated
their treatment without hospital admission or emergency depart-
ment care.
Operative characteristics for resected patients
Twelve patients were resected following neoadjuvant therapy
(Table 3). Of these, five (42%) required venous resection; three
patients underwent primary repair of the PV, one patient had
primary repair of the SMV and PV, and one patient underwent
SMV/PV reconstruction using internal jugular vein. Margin-
negative (R0) resection was achieved in all five of these patients
Table 1 Patient characteristics
Resected patients (n = 12) Unresected patients (n = 14) P-value
Age, years, mean  SD 64.6  8.0 61.7  11.3 NS
Gender, % male : % female 58 : 42 50 : 50 NS
Symptoms at diagnosis, n (%)
Jaundice 7 (58%) 6 (43%) NS
Abdominal pain 8 (67%) 10 (71%) NS
Tumour size at diagnosis, cm, mean  SD 3.2  0.8 3.7  1.4 NS
CA 19-9 at diagnosis (adjusted), U/ml, mean  SDa 370  641 130  189 NS
‘Borderline’ anatomic characteristic, n (%)
SMV involvement (>180) 7 (58%) 6 (43%) NS
SMA abutment (<180) 1 (8%) 4 (29%) NS
Short segment SMV/PV occlusion 1 (8%) 1 (7%) NS
Hepatic artery encasement 0 (0%) 1 (7%) NS
Possible nodal or metastatic disease, n (%) 3 (25%) 2 (14%) NS
Poor performance status, n (%) 0 (0%) 0 (0%) NS
a Adjusted by dividing CA 19-9 by total bilirubin
SD, standard deviation; NS, not significant
Table 2 Neoadjuvant therapies
Resected patients (n = 12) Unresected patients (n = 14) P-value
ChemoXRT alone, n (%) 1 (8%) 4 (29%) NS
Chemotherapy alone, n (%) 8 (67%) 7 (50%) NS
Gemcitabine alone 4 (33%) 2 (14%) NS
Gemcitabine + cisplatin 1 (8%) 0 (0%) NS
Gemcitabine + oxaliplatin 0 (0%) 1 (7%) NS
Gemcitabin + Tarceva 2 (17%) 3 (21%) NS
Gemcitabine, oxaliplatin, Tarceva 1 (8%) 1 (7%) NS
ChemoXRT, then chemotherapy, n (%) 2 (17%)a 2 (14%)b NS
Unknown, n (%) 1 (8%) 1 (7%) NS
Duration of therapy, days, mean  SD 104  37 121  73 NS
a One patient received gemcitabine alone after chemoXRT, one patient received gemcitabine, oxaliplatin and Tarceva after chemoXRT
b Both patients received gemcitabine/Tarceva after chemoXRT
ChemoXRT, chemoradiotherapy; NS, not significant; SD, standard deviation
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and they did not experience increased morbidity compared with
the remainder of this patient population.
The 30-day mortality rate in our series was 0%. Eight of 12
patients (67%) experienced a complication, although all of these
were minor. Two patients each suffered intra-abdominal abscess
(one treated by percutaneous drainage, one by antibiotics alone),
type A pancreatic fistula (drains were removed in both patients at
the first postoperative visit after output had decreased substan-
tially), Clostridium difficile colitis treated with antibiotics, urinary
tract infection and wound infection. Two patients were
re-admitted within 30 days of the operation, one for hypoglycae-
mia and one for cellulitis at the feeding tube site. No patients
underwent re-operation.
The mean tumour size of resected cancers was 3.5 1.8 cm. Six
patients (50%) had moderate-grade tumour; five (42%) had poor
differentiation. Five patients (42%) also had lymph nodes positive
for disease in the resection specimen; a mean of 12.4 5.2 lymph
nodes were removed per operation. Eight of our operations (67%)
resulted inmargin-negative (R0) resections. The other four opera-
tions (33%) resulted in R1 resections; three of these reflected
microscopically positive retroperitoneal margins and one resulted
from a positive pancreatic margin upon final pathological analy-
sis, which had been deemed negative by intraoperative frozen
section. Of the five patients undergoing venous resection, venous
structures were uninvolved by tumour in four; the fifth patient’s
tumour invaded through the resected portion of the PV. Our
practice is to resect veins that appear abnormal during the proce-
dure, although these findings may indicate desmoplastic reaction
secondary to tumour or therapy, rather than direct tumour
involvement.
Survival
Survival was analysed by the Kaplan–Meier log rank method
(Table 4, Fig. 2). The median survival for resected patients was
23.3 months (range 9.8–33.4 months) vs. 15.5 months (range
6.2–18.8 months) for unresected patients, a difference that
reached significance (P = 0.015). Five of the 12 resected patients
are still alive, with current survivals of 14.5–27.0 months; two of
14 unresected patients are alive, with survivals of 18.2 and 18.8
months. Median survival following the completion of neoadju-
vant therapy was also significantly longer in the resected group
(20.0 months [range 4.7–29.5 months] vs. 9.2 months [range
2.0–14.5 months]; P = 0.023).
The median time to tumour recurrence in the resected group
was 4.7 months. Of the nine resected patients for whom recur-
rence data is known, five (56%) recurred within 6 months of
surgery, three in the operative bed (33%), and two as peritoneal
metastases (22%); none of these patients received adjuvant
therapy. Two patients (22%) received chemoradiation adjuvantly
and had distant metastatic disease at 9.8 and 21.1 months post-
operatively. An additional two patients (22%) have not yet
recurred; they have current postoperative durations of 17.1 and
19.4 months and both received adjuvant chemoradiation. Of the
three patients with positive retroperitoneal margins, one received
no adjuvant therapy and recurred locally within 6 months, one
received adjuvant chemoradiation and recurred distantly at 9.8
months, and one received adjuvant chemoradiation and has not
yet recurred at 17.1 months postoperatively. The one patient with
a positive pancreatic margin has been lost to follow-up.
Discussion
Patients with borderline resectable pancreatic cancer treated by
initial surgical resection can be expected to have worse surgical
and survival outcomes compared with patients with resectable
disease because of the increased complexity of surgery, the
advanced nature of the tumour, and the high risk for margin-
positive resection. Neoadjuvant treatment for borderline resect-
able tumours can distinguish patients who are likely to benefit
from attempted pancreaticoduodenectomy from non-responders
Table 3 Operative and pathological characteristics for resected
patients and tumours
Operative Resected
patients (n = 12)
Venous resection, n (%) 5 (42%)
Primary repaira 4 (33%)
Reconstruction, n (%)b 1 (8%)
Operative time, min, mean  SD 467  105
Estimated blood loss, ml, mean  SD 679  392
Length of stay, days, mean  SD 15.0  6.7
30-day mortality, n (%) 0 (0%)
30-day morbidity, n (%) 8 (67%)
Intra-abdominal abscess 2 (17%)
Pancreatic fistula, type A 2 (17%)
Clostridium difficile colitis 2 (17%)
Urinary tract infection 2 (17%)
Wound infection 2 (17%)
30-day hospital readmission, n (%) 2 (17%)
Pathological
Tumour size, cm, mean  SD 3.5  1.8
Tumour grade, n (%)
Moderate 6 (50%)
Poor 5 (42%)
Lymph node positive, n (%) 5 (42%)
Lymph nodes removed, mean  SD 12.4  5.2
Margin status, n (%)
R0 8 (67%)
R1 4 (33%)
a Portal vein: three patients; superior mesenteric vein/portal vein: one
patient
b Superior mesenteric vein/portal vein reconstructed using internal
jugular vein in one patient
SD, standard deviation
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who are unlikely to have longterm survival with or without resec-
tion. Additionally, this strategy allows for the early treatment of
micrometastatic disease, increases the probability that the treat-
ment course will be promptly completed without delays caused by
postoperative recovery, and maximizes the potential for margin-
negative resection in tumours that respond to treatment.1
Our radiographically defined criteria for borderline resectabil-
ity include the MDAnderson criteria and an objectified definition
of unilateral SMV/PV impingement, specifically those tumours
involving >180 degrees of vessel circumference. In accordance
with the NCCN guidelines, tumours with such substantial venous
involvement should be considered to be borderline resectable
because R0 resection typically requires complex venous recon-
struction that can be avoided by attempted downstaging with
neoadjuvant treatment. The MD Anderson group has further
expanded the definition of borderline resectable disease by includ-
ing patients who are anatomically resectable, but who have ques-
tionable metastatic disease or poor performance status. The
inclusion of these patients obviously prevents the substage of bor-
derline resectable disease from being defined only by objective
anatomic criteria, and complicates the design of future trials to
determine optimal treatment strategies for tumours bearing spe-
cific anatomic borderline characteristics. However, for the pur-
poses of this review, as patients with questionable metastases or
poor performance status are often initially treated as anatomically
borderline resectable patients because of their marginally oper-
able status, we included them in our analysis.4 In the MD Ander-
son retrospective analysis of patients with borderline resectable
disease, outcomes for patients with questionable metastases and
poor performance status were not significantly different than
those for patients with anatomically borderline resectable disease
in terms of the percentage of patients undergoing resection,
achievement of R0 resection and nodal status at resection.
Although they were not compared directly, survival rates were
similar in all three groups of patients; these findings support the
concept of grouping these patients clinically into a single substage
of disease.4
In this series, we have established that resection following neo-
adjuvant treatment in borderline resectable pancreatic cancer can
be accomplished with minimal mortality and reasonable morbid-
ity.We achieved margin-negative resection in eight of 12 patients,
a rate of 67%. This is lower than the 94% reported in the MD
Anderson series; several factors could explain this discrepancy.
One factor may concern the neoadjuvant therapies administered
and their effectiveness at maximally downstaging the tumour. In
our series, the majority of patients received either chemotherapy
or chemoradiation alone; only four of 26 (15%) received both and
all of these received chemoradiation followed by chemotherapy.
By contrast, 74% and 95% of patients in the MD Anderson series
received neoadjuvant chemotherapy and chemoradiation, respec-
tively, meaning that most patients received both, with the chemo-
therapy occurring first in most patients. In addition, although
both institutions utilized a multidisciplinary group and consid-
ered similar factors in determining which patients should undergo
resection, it is possible that our group attempted resection more
often in patients with less favourable tumour biology or clinical
status; the MD Anderson group reported that 16% of operations
were aborted on findings of abdominal metastases at laparotomy,
whereas this occurred in four of our 16 operations (25%). Finally,
the differences may simply reflect the small number of resected
patients in our series.
Table 4 Survival rates
Resected
patients (n = 12)
Unresected
patients (n = 14)
P-value
Overall survival, months, median (range) 23.3 (9.8–33.4)a 15.5 (6.2–18.8)b 0.015
Survival following neoadjuvant treatment, months, median (range) 20.0 (4.7–29.5)c 9.2 (2.0–14.5)d 0.023
Time to recurrence, months, median (range) 4.7 (2.1–21.4)e – –
a Includes five living patients, current survivals of 14.5–27.0 months
b Includes two living patients, current survivals of 18.2 and 18.8 months
c Includes five living patients, current post-neoadjuvant survivals of 8.9–22.7 months
d Includes two living patients, current post-neoadjuvant survivals of 11.5 and 14.5 months
e Two patients have not recurred at 17.1 and 19.4 months post-resection, respectively
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Figure 2 Kaplan–Meier overall survival curve. Median survival was
23.3 months (range 9.8–33.4 months) in the resected group and 15.5
months (range 6.2–18.8 months) in the unresected group
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The median time to recurrence following surgery in our
resected patients, 4.7 months, was shorter than that reported pre-
viously. In the European Study Group for Pancreatic Cancer’s
ESPAC-1 trial, the median time to recurrence following resection
for Stage I/II disease ranged from 9.4 to 15.3 months, with longer
times achieved in patients treated with adjuvant chemotherapy.8
In the MD Anderson trial of borderline resectable patients, the
median time to recurrence was 24 months.4 Overall, 20% of MD
Anderson patients and five (42%) of ours were treated with adju-
vant therapy, although, as mentioned above, the nature of the
neoadjuvant and adjuvant therapies received are likely to have
differed substantially between the two institutions. Although our
median time to recurrence was low, this result reflected a bimodal
distribution, in which half of our resected patients recurred
within 10 months of surgery; only one of these patients received
adjuvant therapy. By contrast, three patients (25%) demonstrated
disease-free survival of >17 months after surgery, and two of these
have not yet recurred; one received neoadjuvant and adjuvant
chemotherapy and chemoradiation, whereas the other two
received neoadjuvant chemotherapy and adjuvant chemoradia-
tion. As for all patients with pancreatic adenocarcinoma,
recurrence-free and overall survivals will continue to increase as
chemotherapy and chemoradiation strategies are optimized. The
bimodal distribution of our outcomes also suggests that data from
larger sample sizes in the future may help to elucidate prognostic
factors that could be used to guide individual therapy, including
the decision to attempt resection.
Not surprisingly, overall survival rates were longer in patients
who were successfully resected following neoadjuvant treatment
(23.3 months), compared with those whose disease progressed
and who did not undergo resection (15.5 months). Median sur-
vival for all unresected patients identified during the 5-year period
(intent-to-treat) was 14.1 months; this is higher than that
reported for patients with locally advanced disease who undergo
chemoradiation or chemotherapy (6–7 months) and similar to
that reported for unresected borderline resectable disease (15
months).3,4 The relatively prolonged survival that we observed in
the unresected group may simply reflect favourable tumour
biology in our small set of patients, an effect that may not be
observed in a larger series. Our survival rates for resected patients
were similar to the 20-month survival rates that have been
reported in patients with Stage I/II disease treated by initial resec-
tion.8 The margin-negative resection rate in our small series of
patients (67–73%) is likewise similar to that seen in previous trials
of resectable patients (80–83%).1,8 As in the MD Anderson series,
only about 40% of our patients presenting with borderline resec-
table disease were successfully resected and no clinical character-
istics of the patients or tumours distinguished this group from
unresectable patients at the time of initial presentation. A neoad-
juvant treatment strategy for patients with borderline resectable
pancreatic cancer allows for the selection of those patients who are
most likely to benefit from surgery and thus spares others the
morbidity of the procedure. Although we found that the results
for patients with borderline resectable disease were similar to
those for initially resectable patients, the results may improve as
our understanding of the treatment of this subset of patients
grows. Furthermore, neoadjuvant treatment does not negatively
impact the survival of borderline resectable patients who are ulti-
mately resected, compared with initially resectable patients, and
should be considered standard treatment for patients presenting
with borderline resectable disease.
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